Clinical Research Directory

Inclusion Criteria: * Subjects must have a documented diagnosis of adult-onset axial Spondyloarthritis (axSpA) with at least 3 months' symptom duration and meet the Assessment of SpondyloArthritis International Society (ASAS) criteria * Subjects must have active disease at Screening as defined by * Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score \>= 4 * Spinal pain \>= 4 on a 0 to 10 Numerical Rating Scale (NRS; from BASDAI item 2) * Nonradiographic (Nr)-axSpA subjects must either have C-reactive protein (CRP) \> upper limit of normal (ULN) and /or current evidence of sacroiliitis on magnetic resonance imaging (MRI) (no confirmation by central reading) as defined by ASAS criteria * Ankylosing spondylitis (AS) subjects must have evidence of sacroiliitis on x-ray meeting the modified New York (mNY) classification criteria according to the Investigator * Subjects must have a documented history of Anterior Uveitis (AU) diagnosed by an ophthalmologist and have at least 2 AU flares in the past, of which at least 1 AU flare was in the last 12 months prior to Baseline Exclusion Criteria: * Other inflammatory arthritis * Secondary, noninflammatory condition that, in the Investigator's opinion, is symptomatic enough to interfere with evaluation of the effect of study drug on the subject's primary diagnosis of axial spondyloarthritis (axSpA) * Any history of uveitis except for Anterior Uveitis (AU) associated with axSpA * Any condition or complicating factor that may interfere with the AU assessment * Retisert® or Iluvien® (glucocorticosteroid implant) within 3 years prior to the Baseline Visit or has had complications related to the device * Subject has had Retisert or Iluvien (glucocorticosteroid implant) removed within 90 days prior to the Baseline Visit * Intraocular or periocular corticosteroids within 90 days prior to the Baseline visit * Ozurdex® (dexamethasone implant) within 6 months prior to the Baseline Visit * Cyclophosphamide within 30 days prior to the Baseline Visit * Intravitreal methotrexate (MTX) within 90 days prior to the Baseline Visit * Intravitreal anti-vascular endothelial growth factor (VEGF) therapy